Publications
-
- Conference presentation
- [AACR 2025] DA-4701: Discovery of SC2073 (IN-207039), a potent and mutant selective EGFR degrader that overcomes 3rd generation EGFR inhibitors resistance in NSCLC
-
- Conference presentation
- [EORTC-NCI-AACR 2024] DA-4515, The novel potent Pan-TEAD inhibitor, SB6863, inhibits oncogenic YAP1/TAZ-TEAD signaling and exhibits robust tumor regression in preclinical mesothelioma models
-
- Conference presentation
- [AAIC 2024] DA-7503, a novel tau aggregation inhibitor, ameliorates tau pathology and reduces CSF tau in transgenic mouse models of Alzheimer’s disease and primary tauopathies
-
- Conference presentation
- [ADA 2024] DA-1726, a GLP1R/GCGR Dual Agonist, A Promising Approach in Body Composition and Lipid Management
-
- Conference presentation
- [KSBMB 2024] DA-1241, a GPR119 agonist, ameliorates fatty liver through the upregulation of TFEB mediated autophagy
-
- Conference presentation
- [EASL 2024] DA-1241, a GPR119 agonist, combined with Semaglutide synergistically improved liver fibrosis in mice with CCl4-induced liver fibrosis
-
- Conference presentation
- [EASL 2024] Additive hepatoprotective effects of DA-1241, a novel GPR119 agonist, in combination with semaglutide in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH
-
- Conference presentation
- [AACR 2024] A first-in class SHP1 allosteric inhibitor, SB8091, shows a good efficacy and safety profile in preclinical models
-
- Conference presentation
- [AACR-NCI-EORTC 2023] A first-in class and highly selective SHP1 allosteric inhibitor exhibits robust anti-tumor immunity and synergizes with PD-1 blockade
-
- Conference presentation
- [ADA 2023] A Novel GLP1R/GCGR Dual Agonist, DA-1726 Elicits Weight Loss Superior to Semaglutide in Diet-Induced Obese Rats